Biomarkers in spondyloarthropathies

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 122-132

  Chen, Chun Hsiung ^a   Yu, David Tak Yan ^a   Chou, Chung Tei ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; BIOLOGICAL MARKER; C PROPEPTIDE OF TYPE II COLLAGEN; C REACTIVE PROTEIN; COLLAGEN TYPE 2; COLONY STIMULATING FACTOR 1; EPITOPE; ETANERCEPT; GELATINASE B; INFLIXIMAB; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; SERUM AMYLOID A; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MOLECULAR DYNAMICS; OSTEOARTHRITIS; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SPONDYLOARTHROPATHY; TREATMENT DURATION; TURNOVER TIME; HOSPITALIZATION; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 3; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 70349577788     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_9     Document Type: Article

References (62)

1. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 2005; 44:1483-91. (Pubitemid 41742463)
2. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21:2286-91.
3. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817-824. (Pubitemid 37026490)
4. Sheehan NJ, Slavin BM, Donovan MP et al. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 1986; 25:171-4. (Pubitemid 16033798)
5. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26:966-70. (Pubitemid 29195695)
6. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346:1349-56. (Pubitemid 34754607)
7. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab : A randomised controlled multicentre trial. Lancet 2002; 359:1187-93. (Pubitemid 34304258)
8. Bauer DC, Hunter DJ, Abramson SB et al. Osteoarthritis biomarkers network. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14:723-7. (Pubitemid 43986366)
9. Huang F, Zhu J, Zhang L et al. Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. Clin Rheumatol 2007; 26:920-6. (Pubitemid 46951290)
10. Kruithof E, De Rycke L, Vandooren B et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54:1795-804. (Pubitemid 43877929)
11. Pepe MS, Janes H, Longton G et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159:882-90. (Pubitemid 38657490)
12. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-4.
13. Ishiguro N, Ito T, Miyazaki K et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1999; 26:34-40. (Pubitemid 29051392)
14. Ishiguro N, Ito T, Obara K et al. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996; 23:1599-604. (Pubitemid 26290588)
15. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59:455-61. (Pubitemid 30395603)
16. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circ Res 2003; 92:827-39. (Pubitemid 36542523)
17. Grillet B, Dequeker J, Paemen L et al. Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody. Br J Rheumatol 1997; 36:744-7.
18. Hembry RM, Bagga MR, Reynolds JJ et al. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors. TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheuatoid arthritis. Ann Rheum Dis 1995; 54:25-32.
19. Okada Y, Takeuchi N, Tomita K et al. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B-cells): Correlation with rheumatoid arthritis. Ann Rheum Dis 1989; 48:645-53. (Pubitemid 19201961)
20. Ahrens D, Koch AE, Pope RM et al. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39:1576-87. (Pubitemid 26314993)
21. Cole AA, Chubinskaya S, Schumacher B et al. Chondrocyte matrix metalloproteinase-8. Human articular chondrocytes express neutrophil collagenase. J Biol Chem 1996; 271:11023-6.
22. Mohtai M, Smith RL, Schurman DJ et al. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993; 92:179-85. (Pubitemid 23208994)
23. MacNaul KL, Chartrain N, Lark M et al. Discoordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990; 265:17238-45.
24. Zhang Y, McCluskey K, Fujii K et al. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage, CSF and IL-1 beta through prostaglandin-dependent and independent mechanisms. J Immunol 1998; 161:3071-6. (Pubitemid 28425734)
25. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92:827-839. (Pubitemid 36542523)
26. Manicourt DH, Fujimoto N, Obata K et al. Levels of circulating collagenase, stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995; 38:1031-9.
27. Manicourt DH, Fujimoto N, Obata K et al. Serum levels of collagenase, stromelysin-1 and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994; 37:1774-83. (Pubitemid 24371880)
28. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378:151-60. (Pubitemid 27230597)
29. Vandooren B, Kruithof E, Yu DT et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942-2953. (Pubitemid 39209533)
30. Chen CH, Lin KC, Yu DT et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006; 45:414-20.
31. Chen CH, Liao HT, Chen HA et al. Serum levels of matrix metalloproteinase-3 in undifferentiated spondyloarthropathy. Scand J Rheumatol 2007; 36:326-8.
32. Yang C, Gu J, Rihl M et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51:691-699. (Pubitemid 39372026)
33. Maksymowych WP, Poole AR, Hiebert L et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005; 32:1911-1917. (Pubitemid 41429021)
34. Maksymowych WP, Jhangri GS, Lambert RG et al. Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29:959-965. (Pubitemid 34493501)
35. Woo JH, Lee HJ, Sung IH et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol; in press.
36. Maksymowych WP, Landewe R, Conner-Spady B et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56:1846-53. (Pubitemid 47110384)
37. Creemers MC, Franssen MJ, van't Hof MA et al. Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. Ann Rheum Dis 2005; 64:127-9. (Pubitemid 40075289)
38. Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007; 3:346-56. (Pubitemid 46864889)
39. Billinghurst RC, Dahlberg L, Ionescu M et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99:1534-45. (Pubitemid 27163804)
40. Kojima T, Mwale F, Yasuda T et al. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001; 44:120-7. (Pubitemid 32113126)
41. Nelson F, Dahlberg L, Laverty, S et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 102:2115-25. (Pubitemid 29018818)
42. Poole AR. Cartilage in health and disease. In: Koopman W, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. 14th ed. Philadelphia: Lippincott, Williams and Wilkins, 2001; 226-84.
43. Poole AR, Howell DS. Etiopathogenesis of osteoarthritis. In: Moskowitz RV, Howell DS, Goldberg VM, Mankin HJ, eds. Osteoarthritis: Diagnosis and Management. 3rd ed. Baltimore: Saunders, 2001; 29-47.
44. Kim TH, Stone M, Payne U et al. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005; 52:885-91. (Pubitemid 40365112)
45. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-505.
46. François RJ, Neure L, Sieper J et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006; 65:713-20. (Pubitemid 43799168)
47. Yang PT, Kasai H, Xiao WG et al. Increased expression of macrophage colony-stimulating factor in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 2006; 65:1671-2. (Pubitemid 44799690)
48. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265:501-23. (Pubitemid 29488982)
49. O'Hara R, Murphy EP, Whitehead AS et al. Acute-phase serum amyloid a production by rheumatoid arthritis synovial tissue. Arthritis Res 2000; 2:142-4.
50. Vallon R, Freuler F, Desta-Tsedu N et al. Serum amyloid a (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166:2801-7. (Pubitemid 32173521)
51. Strissel KJ, Girard MT, West-Mays JA et al. Role of serum amyloid A as an intermediate in the IL-1 and PMA-stimulated signaling pathways regulating expression of rabbit fibroblast collagenase. Exp Cell Res 1997; 237:275-87. (Pubitemid 28027922)
52. Dowton SB, Peters CN, Jestus JJ. Regulation of serum amyloid a gene expression in syrian hamsters by cytokines. Inflammation 1991; 15:391-7.
53. Migita K, Kawabe Y, Tominaga M et al. Serum amyloid a protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1998; 78:535-9. (Pubitemid 28246977)
54. O'Hara R, Murphy EP, Whitehead AS et al. Local expression of the serum amyloid a and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004; 50:1788-99. (Pubitemid 38725091)
55. Jung SY, Park MC, Park YB et al. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 2007; 48:218-24. (Pubitemid 46711751)
56. Lange U, Boss B, Teichmann J et al. Serum amyloid A - An indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000; 19:119-22. (Pubitemid 30242746)
57. Gratacós J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33:927-31. (Pubitemid 24324807)
58. Bal A, Unlu E, Bahar G et al. Comparison of serum IL-1 beta, sIL-2R, IL-6 and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26:211-5. (Pubitemid 46020247)
59. Gratacos J, Collado A, Pons F et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999; 42:2319-24. (Pubitemid 30333411)
60. Visvanathan S, Wagner CL, Marini JC et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis in press.
61. Falkenbach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 1998; 18:103-6. (Pubitemid 28505331)
62. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43:1346-52. (Pubitemid 30416320)